Arch Biopartners Expands Phase II Trial for Cardiac Surgery Kidney Injury Treatment
Event summary
- Fraser Health Authority and Arch Biopartners signed a Clinical Trial Agreement for Phase II trial of LSALT peptide in cardiac surgery-associated acute kidney injury (CS-AKI).
- Royal Columbian Hospital becomes the ninth global site and fourth Canadian site in the trial, with final approvals received.
- Three other Canadian hospitals continue active patient enrollment in the trial.
- Arch is in feasibility discussions with additional cardiac surgery centers in Canada and the U.S.
The big picture
This expansion of Arch Biopartners' Phase II trial reflects growing institutional interest in novel treatments for cardiac surgery-associated acute kidney injury, a condition affecting a significant portion of cardiac surgery patients. The addition of Royal Columbian Hospital as the fourth Canadian site suggests strong regional support for the study, while ongoing discussions with U.S. centers indicate potential for further international growth. With over 800 million people worldwide affected by kidney disease, successful outcomes from this trial could position Arch as a key player in addressing this critical unmet medical need.
What we're watching
- Trial Momentum
- Whether the addition of Royal Columbian Hospital will accelerate patient recruitment and data collection.
- Geographic Expansion
- The pace at which Arch can activate additional sites in North America to support the Phase II trial.
- Regulatory Pathway
- How successful trial results might position LSALT peptide for future regulatory approvals in key markets.